Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat vs rhEPO in Hemodialysis-Dependent CKD Anemia
NCT01587924Phase 2Completed
- Sponsor
- GSK
- Start
- May 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of daprodustat in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by GSK. Primary endpoint: Modeled Hemoglobin (Hgb) Change From Baseline at 4 weeks. Started May 2012; status: completed.
02
Drugs
daprodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT01587924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01587924.